

PERSONALIZED BIOENGINEERED SKIN GRAFTS

Problem – Challenge

Every year in the world, more than 50 millions of people suffer from skin defects and need surgical intervention to restore skin function. Skin defects can be either acute (burns & trauma) or elective (reconstructive and ulcers). In many cases, standard of care leaves patients with debilitating scars.

Solution


CUTISS is a Swiss biotech company, spin-off of the University of Zurich (UZH), developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its first in line product denovoSkin™ has been tested in a phase I clinical trial on pediatric patients at the University Children's Hospital in Zurich. EU phase II studies are about to start funded by Wyss Zurich, a joint accelerator of UZH and ETHZ. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ promises to improve life quality of elective (reconstructive) patients as well and it can further be developed in terms of complexity by adding pigmentation.

In EU and US about 12 million patients could benefit from CUTISS' technology every year. denovoSkin™ could significantly improve the life quality of patients worldwide by drastically reducing scarring after transplantation. CUTISS closed a seed financing round of CHF 1 million with the UZH Life Sciences Fund (UZH LSF). UZH LSF has been established by UZH and Novartis Venture Fund with the goal to create financing possibilities for UZH spin-off companies. These ventures are often in a very early stage of development. UZH LSF aims to promote innovation in the life sciences in the Zurich area.



**Universität
Zürich**^{UZH}

CUTISS
personalized skin



Skin graft (copyright Wyss Zurich)